Breaking Finance News

A statement released earlier today by Jefferies Group about Aratana Therapeutics Inc (NASDAQ:PETX) bumps the target price to $13.00

Jefferies Group raised the target price of Aratana Therapeutics Inc (NASDAQ:PETX) to $13, stating a possible upside of 0.41%.

Boasting a price of $9.25, Aratana Therapeutics Inc (NASDAQ:PETX) traded 0.33% higher on the day. With the last stock close up 36.93% from the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same time. Aratana Therapeutics Inc has logged a 50-day moving average of $8.72 and two hundred day moving average of $6.71. 512,794 shares of Aratana Therapeutics Inc were exchanged, down from ann avg. trading volume of 706,606

Performance Graphic:

Aratana Therapeutics Inc (NASDAQ:PETX)

With a market capitalization of $0.0, Aratana Therapeutics Inc has a one-year low of $2.56 and a one-year high of $19.99 with a price-earnings ratio of 0.

Also covering Aratana Therapeutics Inc’s price target, a total of 7 equity analysts have issued a ratings update on Aratana Therapeutics Inc. The average target price is $12.29 with three firms rating the stock a strong buy, five firms rating the stock a buy, one firm rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firmsrating the stock as sell.

Brief Synopsis About Aratana Therapeutics Inc (NASDAQ:PETX)

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, and AT-016 and AT-018 for dogs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.